Valuation: Novartis

Market Cap 295B 259B 241B 221B 416B 28,438B 422B 2,864B 1,119B 13,981B 1,109B 1,085B 48,339B P/E 2026 *
21.6x
P/E 2027 * 18.6x
Enterprise Value 328B 288B 268B 246B 463B 31,627B 470B 3,185B 1,244B 15,549B 1,233B 1,206B 53,760B EV / Sales 2026 *
5.71x
EV / Sales 2027 * 5.3x
Free-Float
91.66%
Yield 2026 *
2.81%
Yield 2027 * 2.94%
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Chief Tech/Sci/R&D Officer 64 2022-05-15
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+1.43%+48.50%+160.39% 1,057B
+1.59%+4.09%+55.34%+53.96% 624B
+0.95%+1.91%+35.91%+81.14% 454B
+1.60%+7.09%+35.90%+29.32% 341B
-0.14%+0.33%+18.70%+17.64% 262B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+2.66%+21.87%+59.73% 201B
-1.18%-3.70%+14.23%+66.51% 162B
-0.16%-2.04%-3.20%-34.58% 143B
Average +0.41%+0.32%+22.18%+43.55% 384.39B
Weighted average by Cap. +0.61%+1.31%+34.56%+76.17%

Financials

2026 *2027 *
Net sales 57.51B 50.51B 46.98B 43.11B 81B 5,539B 82.24B 558B 218B 2,723B 216B 211B 9,415B 60.99B 53.57B 49.82B 45.71B 85.89B 5,873B 87.22B 592B 231B 2,888B 229B 224B 9,984B
Net income 13.97B 12.27B 11.41B 10.47B 19.67B 1,345B 19.98B 135B 52.94B 661B 52.44B 51.31B 2,287B 15.64B 13.73B 12.77B 11.72B 22.02B 1,506B 22.36B 152B 59.25B 740B 58.7B 57.43B 2,560B
Net Debt 33.11B 29.08B 27.05B 24.82B 46.63B 3,189B 47.35B 321B 125B 1,568B 124B 122B 5,421B 27.82B 24.43B 22.72B 20.85B 39.17B 2,679B 39.78B 270B 105B 1,317B 104B 102B 4,554B
Logo Novartis
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA